BofA lowered the firm’s price target on Teladoc (TDOC) to $9.50 from $11 and keeps a Neutral rating on the shares. Sensor Tower trends suggest Q1 total revenue is tracking towards the low-end of Teladoc’s revenue guidance and slightly below consensus, says the analyst, who sees value in the core network offering but remains cautious on BetterHelp trends and weak trends in Livongo.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Cautious Hold on Teladoc Amidst Declining User Growth and Uncertain Initiatives
- Telehealth companies aggressively marketing hair-loss medicine to men, WSJ says
- Cylinder joins Teladoc Health’s connected care program
- Cylinder announces partnership with Teladoc Health
- Teladoc expands connected care partnerships